Wealth Enhancement Advisory Services
CRMD icon

Wealth Enhancement Advisory Services’s CorMedix CRMD Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$306K Buy
36,469
+12,164
+50% +$96.1K ﹤0.01% 3184
2026
Q1 		$171K Sell
24,305
-3,235
-12% -$23.9K ﹤0.01% 3190
2025
Q4 		$310K Buy
27,540
+1,707
+7% +$18.9K ﹤0.01% 2895
2025
Q3 		$286K Sell
25,833
-3,281
-11% -$39.7K ﹤0.01% 2840
2025
Q2 		$338K Buy
29,114
+1,478
+5% +$16.3K ﹤0.01% 2550
2025
Q1 		$170K Sell
27,636
-3,409
-11% -$35.3K ﹤0.01% 2663
2024
Q4 		$251K Sell
31,045
-21,139
-41% -$211K ﹤0.01% 2517
2024
Q3 		$422K Buy
52,184
+4,935
+10% +$26.7K ﹤0.01% 1939
2024
Q2 		$205K Buy
47,249
+3,064
+7% +$15.6K ﹤0.01% 2283
2024
Q1 		$187K Buy
44,185
+1,157
+3% +$4.01K ﹤0.01% 2215
2023
Q4 		$162K Buy
43,028
+1,955
+5% +$6.73K ﹤0.01% 2120
2023
Q3 		$152K Buy
+41,073
New +$163K ﹤0.01% 2045

Other funds holding CRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
OAM
Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Wealth Enhancement Advisory Services's CRMD Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its CorMedix (CRMD) stake by 50% in Q2 2026, buying an estimated $96.1K and bringing the position to 36,469 shares worth $306K. The position accounts for ﹤0.01% of the portfolio, ranked #3184.

Wealth Enhancement Advisory Services first reported a position in CRMD in Q3 2023 and has held it in 12 quarters since. The position peaked at $422K in Q3 2024. 194 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.

  • Wealth Enhancement Advisory Services held 36,469 shares of CorMedix worth $306K as of Q2 2026.
  • Wealth Enhancement Advisory Services bought 12,164 CorMedix shares in Q2 2026, an estimated $96.1K.
  • CorMedix made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #3184 holding.
  • Wealth Enhancement Advisory Services first reported a position in CorMedix in Q3 2023 and has held it in 12 quarters since.
  • Wealth Enhancement Advisory Services's CorMedix position peaked at $422K in Q3 2024.
  • 194 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.